Bio-path Holdings, INC 8-K filings

Bio-Path Holdings announces strategic shifts including a new Series B Preferred stock, a pivot to cryptocurrency treasury management, and engagement of an advisor for biotech IP divestiture.

Bio-Path Holdings, Inc. disclosed significant strategic repositioning, including a digital asset treasury initiative and the potential acquisition of a substantial legal judgment.

Bio-Path Holdings, Inc. announced a shift in voting control to its CEO's advisory firm, plans for corporate domestication, and efforts to restart drug trials amid financial restructuring.

Bio-Path Holdings announced a board resignation and is actively seeking financing to support a company turnaround, warning of going concern risks if capital is not secured.

Bio-Path Holdings, Inc. announced the appointment of Vikram Grover as President, Chief Executive Officer, and Chief Financial Officer, alongside changes to its Board of Directors.

Bio-Path Holdings, Inc. has dismissed Ernst & Young LLP as its independent registered public accounting firm, effective August 13, 2025.

Bio-Path Holdings, Inc. has announced the resignation of its President and CEO, along with two other board members, and has instituted a company-wide operational pause, furloughing most employees, as it seeks additional financing.

Bio-Path Holdings reports positive pre-clinical results for BP1001-A, showing potential in treating obesity and related metabolic diseases in Type 2 diabetes patients by preventing insulin resistance.

Bio-Path Holdings enters into a securities purchase agreement with Quick Capital, LLC for a $161,000 promissory note with a 12% interest charge and potential conversion rights upon default.

Bio-Path Holdings enters into a securities purchase agreement for a $100,050 promissory note with 1800 Diagonal Lending LLC, receiving $87,000 after an original issue discount.

Bio-Path Holdings announced a narrowed net loss for the full year 2024 while reporting advancements in its DNAbilize platform clinical trials for obesity and cancer, alongside a critically low cash position highlighting near-term funding requirements.

Bio-Path Holdings reports promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients by attenuating fatty acid-induced insulin resistance and restoring insulin sensitivity.

Bio-Path Holdings enters into a securities purchase agreement for a $161,000 promissory note with 1800 Diagonal Lending LLC, featuring a 12% interest charge and potential conversion to common stock upon default.

Bio-Path Holdings, Inc. received notification from Nasdaq that its common stock will be delisted due to non-compliance with the minimum stockholders' equity requirement.

Bio-Path Holdings provides a clinical and operational update for 2025, emphasizing advancements in its oncology programs and the exploration of BP1001-A for treating obesity in Type 2 Diabetes.

Bio-Path Holdings reports successful preclinical studies of BP1001-A, showing enhanced insulin sensitivity, suggesting its potential as a treatment for obesity and Type 2 diabetes.

Bio-Path Holdings received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement, while also securing shareholder approval for a reverse stock split and an increase in shares available under its stock incentive plan.

Bio-Path Holdings is reallocating resources to develop BP1001-A for obesity and Type 2 diabetes, discontinuing a Phase 1 lymphoma trial due to enrollment challenges.

Bio-Path Holdings has received a conditional extension from the Nasdaq Hearings Panel to maintain its listing, requiring the company to meet a $2.5 million minimum stockholders' equity requirement by January 31, 2025.

Bio-Path Holdings reported its third quarter 2024 financial results, highlighted by the expansion of its DNAbilize technology into obesity treatment and progress in oncology clinical trials.

Bio-Path Holdings has successfully completed a $4 million private placement and announced the initiation of a therapeutic program for obesity, alongside updates on its ongoing AML clinical trial.

Bio-Path Holdings has received a delisting notice from Nasdaq after failing to meet minimum stockholders' equity requirements, but plans to appeal the decision.

Bio-Path Holdings announces promising patient responses in its Phase 1/1b solid tumor trial and Phase 2 AML trial, highlighting the potential of its DNAbilize platform.

Bio-Path Holdings reported a reduced net loss for the second quarter of 2024 and highlighted clinical and corporate progress, including a recent $4 million private placement.

Bio-Path Holdings announces progress in its clinical trials, development of molecular biomarkers, and expansion into preclinical obesity studies.

Bio-Path Holdings has been granted an extension until September 8, 2024, by Nasdaq to meet the minimum stockholders' equity requirement, with potential delisting if compliance is not achieved.

Bio-Path Holdings presented positive interim results from its Phase 2 study of prexigebersen in combination with other drugs for acute myeloid leukemia (AML), showing significant clinical improvement and a tolerable safety profile.

Bio-Path Holdings has successfully completed a $4 million private placement, issuing shares and warrants to an institutional investor to fund working capital and general corporate purposes.

Bio-Path Holdings presented positive interim results from its Phase 2 study of prexigebersen in combination with other drugs for acute myeloid leukemia, showing significant clinical improvement and a tolerable safety profile.

Bio-Path Holdings will present positive interim results from its Phase 2 clinical trial of prexigebersen in acute myeloid leukemia (AML) at both the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) conferences.